Clinical Trial Update: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of NKTR-255 in combination with CAR-T cell therapy for relapsed or refractory large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• Indolent B-cell Non-hodgkin Lymphoma Transformed to Diffuse Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• CAR-T cell therapy
• NKTR-255 (NKTR-255)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Status: ACTIVE_NOT_RECRUITING